Trilaciclib use in extensive-stage small cell lung cancer (ES-SCLC): are clinical benefits seen in the real-world setting?
Trilaciclib, in combination with PEA, demonstrated an improvement in the safety profile without compromising survival outcomes in ES-SCLC patients. These findings underscore the potential benefits of incorporating trilaciclib in real-world clinical settings for enhanced patient care.
Authors
- Christina Billias
- Kristopher Attwood (ORCID: https://orcid.org/0000-0002-7229-5472)
- Joseph Elijah (ORCID: https://orcid.org/0000-0003-3933-473X)
- Grace Kho Dy (ORCID: https://orcid.org/0000-0002-5061-0072)
- Katy Wang
- Prantesh Jain (ORCID: https://orcid.org/0000-0003-2771-4612)
- Eugene Przespolewski (ORCID: https://orcid.org/0000-0001-8149-7431)
- Jeffrey Baron (ORCID: https://orcid.org/0000-0002-9985-3403)
- Allison Holdsworth
Institutions
- Northeastern University (US)
- Roswell Park Comprehensive Cancer Center (US)
- Massachusetts General Hospital (US)
- University at Buffalo, State University of New York (US)
Publication Details
- Journal
- Supportive Care in Cancer
- Published
- 2024-08-31
- DOI
- https://doi.org/10.1007/s00520-024-08828-1
- Citations
- 2
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.57